Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. provided group earnings guidance for the six months ended June 30, 2016. The group is expected to record a significant increase in the profit attributable to the owners of the company for the six months ended June 30, 2016 as compared to the corresponding period in 2015. The increase was mainly due to the fact that the Group disposed of Taizhou Neptunus Nano Bio-medical Technology Company Limited at the end of 2015 and Jiangsu Neptunus Bio-pharmaceutical Company Limited in January 2016, both of which are research and development-focused companies, as a result of the disposals, the Group's corresponding research and development expenses that would have been incurred by these two subsidiaries decreased by approximately RMB 6 million; and the Group repaid partial external borrowings during the Relevant Period, as a result of the repayment, the Group's finance costs for the Relevant Period had decreased by approximately RMB 3 million, as compared to the corresponding period in 2015.